The new prognostic markers indicate that 30-50% of the patients have features portending a poor outcome, and therefore an early start of therapy may be justified in such poor-prognosis groups. This strategy is plausible, considering that continued proliferation and expansion of the neoplastic clone fascilitates accumulation of ominous cytogenetic abnormalities. However, before any recommended guidelines can be proposed, clinical trials must test the use of early intervention in patients in poor prognosis groups.
No comments:
Post a Comment